These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18175324)

  • 1. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9.
    Aruksakunwong O; Malaisree M; Decha P; Sompornpisut P; Parasuk V; Pianwanit S; Hannongbua S
    Biophys J; 2007 Feb; 92(3):798-807. PubMed ID: 17085491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
    Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S
    Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
    Park JW; Jo WH
    J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
    Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
    J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
    Kar P; Knecht V
    J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
    Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
    Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies.
    Yang Z; Nie Y; Yang G; Zu Y; Fu Y; Zhou L
    J Theor Biol; 2010 Dec; 267(3):363-74. PubMed ID: 20831875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
    Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
    Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
    Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site.
    Yusuf M; Mohamed N; Mohamad S; Janezic D; Damodaran KV; Wahab HA
    J Chem Inf Model; 2016 Jan; 56(1):82-100. PubMed ID: 26703840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
    Barrett S; Mohr PG; Schmidt PM; McKimm-Breschkin JL
    PLoS One; 2011; 6(8):e23627. PubMed ID: 21858186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.